X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PANACEA BIOTECH - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PANACEA BIOTECH DISHMAN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 25.1 84.6 29.7% View Chart
P/BV x 3.3 1.9 178.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
DISHMAN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs374149 251.8%   
Low Rs12982 156.6%   
Sales per share (Unadj.) Rs197.884.1 235.1%  
Earnings per share (Unadj.) Rs21.2-18.3 -115.8%  
Cash flow per share (Unadj.) Rs34.7-6.7 -518.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.983.7 214.9%  
Shares outstanding (eoy) m80.6961.25 131.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.4 92.7%   
Avg P/E ratio x11.9-6.3 -188.1%  
P/CF ratio (eoy) x7.2-17.2 -42.0%  
Price / Book Value ratio x1.41.4 101.4%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3067,074 287.0%   
No. of employees `0000.82.8 30.1%   
Total wages/salary Rs m5,3551,449 369.5%   
Avg. sales/employee Rs Th19,252.71,874.1 1,027.3%   
Avg. wages/employee Rs Th6,459.5527.0 1,225.7%   
Avg. net profit/employee Rs Th2,064.1-407.7 -506.2%   
INCOME DATA
Net Sales Rs m15,9615,154 309.7%  
Other income Rs m265100 265.9%   
Total revenues Rs m16,2265,254 308.9%   
Gross profit Rs m4,103-766 -535.5%  
Depreciation Rs m1,091711 153.4%   
Interest Rs m9441,503 62.8%   
Profit before tax Rs m2,334-2,881 -81.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m1-6 -19.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m62417 3,711.9%   
Profit after tax Rs m1,711-1,121 -152.6%  
Gross profit margin %25.7-14.9 -172.9%  
Effective tax rate %26.7-0.6 -4,581.8%   
Net profit margin %10.7-21.8 -49.3%  
BALANCE SHEET DATA
Current assets Rs m11,0183,810 289.2%   
Current liabilities Rs m9,5178,365 113.8%   
Net working cap to sales %9.4-88.4 -10.6%  
Current ratio x1.20.5 254.2%  
Inventory Days Days110156 71.0%  
Debtors Days Days3567 51.8%  
Net fixed assets Rs m16,30414,480 112.6%   
Share capital Rs m16161 263.3%   
"Free" reserves Rs m12,907903 1,429.2%   
Net worth Rs m14,5165,127 283.1%   
Long term debt Rs m4,1895,832 71.8%   
Total assets Rs m29,80519,433 153.4%  
Interest coverage x3.5-0.9 -378.7%   
Debt to equity ratio x0.31.1 25.4%  
Sales to assets ratio x0.50.3 201.9%   
Return on assets %8.92.0 453.6%  
Return on equity %11.8-21.9 -53.9%  
Return on capital %17.53.6 482.1%  
Exports to sales %24.824.5 101.1%   
Imports to sales %3.710.2 36.7%   
Exports (fob) Rs m3,9561,264 313.0%   
Imports (cif) Rs m596525 113.6%   
Fx inflow Rs m4,9521,539 321.7%   
Fx outflow Rs m697942 74.0%   
Net fx Rs m4,255597 712.4%   
CASH FLOW
From Operations Rs m2,786599 465.0%  
From Investments Rs m-1,529-438 349.1%  
From Financial Activity Rs m-941-303 311.0%  
Net Cashflow Rs m316-141 -223.9%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.6 616.7%  
FIIs % 12.7 1.3 976.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 23.6 93.6%  
Shareholders   46,261 10,259 450.9%  
Pledged promoter(s) holding % 35.8 35.1 102.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS